Objective: To evaluate whether time to treatment modifies the effect of endovascular reperfusion in stroke patients with evidence of salvageable tissue on MRI.
Recent endovascular trials have demonstrated benefit from endovascular therapy for patients treated within 6 hours after symptom onset. [1] [2] [3] [4] Whether patients treated outside of this time window also benefit from endovascular therapy remains unknown. Some studies suggest a lack of benefit from endovascular reperfusion beyond 7 hours after symptom onset. 5, 6 However, this time threshold is likely not uniformly valid 7 because the duration of the therapeutic time window depends on the degree to which cerebral blood flow is reduced in an individual patient. [8] [9] [10] Patients with good collaterals can have substantial volumes of salvageable tissue for a relatively long time and may remain good candidates for endovascular treatment even beyond 12 hours after symptom onset. 11, 12 Patient selection in the delayed time window (.6 hours after symptom onset) will therefore have to rely on an assessment of salvageable brain tissue. The best-studied biomarker of salvageable brain tissue is the volumetric mismatch between the magnetic resonance perfusion (MRP) lesion, segmented using a validated threshold, and the diffusion-weighted imaging (DWI) lesion.
The MRP-DWI mismatch hypothesis posits that patients with mismatch benefit from reperfusion regardless of the time at which reperfusion occurs. [14] [15] [16] In this study, we test this hypothesis and investigate whether the association between reperfusion and good clinical outcome depends on the duration between symptom onset and endovascular therapy in patients with an MRP-DWI mismatch.
METHODS Study design and participants. The Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution 2 (DEFUSE 2) study was a prospective multicenter cohort study of patients treated with endovascular reperfusion therapy up to 12 hours after symptom onset. 16 The study enrolled participants between 2008 and 2011. Details of the study protocol, including patient selection criteria, MRI scanning parameters, MRI postprocessing techniques, and the definition of reperfusion, have been reported previously. [16] [17] [18] This subanalysis of the DEFUSE 2 study focused primarily on patients with the target mismatch. Target mismatch is defined as per DEFUSE 2 criteria. 16 Early lesion growth was defined as the difference between the DWI lesion volume at baseline and the DWI lesion volume at early follow-up. Good functional outcome was defined as a 90-day modified Rankin Scale (mRS) score #2.
Standard protocol approvals, registrations, and patient consents. The study complied with the Declaration of Helsinki, the ethics committee at each participating site approved the research protocol, and written informed consent was obtained from all participants or their surrogates.
Statistical analysis. Univariate associations between categorical variables were investigated using x 2 or Fisher exact tests. Continuous and ordinal variables were compared using the Student t test and Mann-Whitney U test. All tests were 2-tailed and considered significant at a ,0.05. The effects of reperfusion and time to endovascular treatment (defined by sheath insertion) on clinical and radiologic outcomes were assessed with multivariable regression analyses. First, using logistic regression, we assessed the effects of reperfusion and time to endovascular treatment on good functional outcome. Using data from all included patients, we built a model with good functional outcome as the dependent variable and with the following independent variables: time to endovascular treatment, reperfusion, and the interaction between these 2 variables. Second, we assessed the effect of time to endovascular treatment on the probability of good functional outcome in the subset of patients with reperfusion. Third, we investigated the effects of time to endovascular treatment, reperfusion, and their interaction on early lesion growth with generalized linear regression analysis. Adjusted effect sizes were calculated by including age and baseline DWI lesion volume as covariates in the models. All analyses were conducted in IBM SPSS 22.0 and SAS 9.4.
RESULTS
Of the 138 patients who consented to participate in the DEFUSE 2 study, the 78 patients who had the target mismatch profile on baseline imaging and underwent endovascular treatment were included in the primary analyses of this study. Baseline characteristics, listed in the table, were well-matched between the early and late treatment groups with the exception of "IV tissue plasminogen activator (tPA) treatment," which was more frequent in the early than in the late endovascular treatment group (66% vs 28%, p 5 0.01). Patients treated early had their baseline MRI a median of 2.8 hours (interquartile range [IQR] 2.1-4.2) after symptom onset, started endovascular treatment 4.8 hours (IQR 3.4-5.4) after symptom onset, and ended the procedure (defined as time of removal of the femoral sheath) 6.5 hours (IQR 5.7-7.2) after symptom onset. Patients in the late treatment group had their baseline MRI a median of 6.2 hours (IQR 5.0-8.2) after symptom onset, started endovascular treatment 7.9 hours (IQR 6.5-9.4) after symptom onset, and ended the procedure 9.3 hours (IQR 8.4-11.0) after symptom onset. The rate of reperfusion was 61% (22 of 36) in the early treatment group and 57% (24 of 42) in the late treatment group (p 5 0.72).
Three predictive models were constructed to assess whether time to treatment alters the association between reperfusion and clinical or radiographic outcomes. First, we constructed models with time to treatment, reperfusion, and the interaction between time to treatment and reperfusion as independent variables. Among target mismatch patients (n 5 78), reperfusion was associated with good functional outcome (odds ratio [OR] adjusted for age, baseline DWI lesion volume, and time to treatment 3.7, 95% confidence interval [CI] 1.2-12, p 5 0.03), but time to treatment (p 5 0.13) and the interaction between time to treatment and reperfusion were not (p 5 0.57) (figure 1). Similarly, among all patients (n 5 105), reperfusion was associated with good functional outcome (adjusted OR 3.5, 95% CI 1.3-9.4, p 5 0.02), whereas time to treatment (p 5 0.27) and the interaction between time to treatment and reperfusion (p 5 0.50) were not. In contrast, among non-target mismatch patients (n 5 21), neither reperfusion (adjusted OR 2.7, 95% CI 0.2-75, p 5 0.47) nor time to treatment (p 5 0.23) nor the interaction between time to treatment and reperfusion (p 5 0.27) was associated with good functional outcome.
The primary analysis was repeated with time to treatment dichotomized into early (#6 hours) vs late (.6 hours) start of endovascular treatment. In target mismatch patients, reperfusion was again associated with good functional outcome (OR adjusted for age, baseline DWI lesion volume, and the dichotomized time-to-treatment variable 4.0, 95% CI 1.3-13, p 5 0.02), whereas time to treatment (p 5 0.56) and the interaction between reperfusion and time to treatment (p 5 0.62) were not. The 90-day mRS outcomes, stratified by reperfusion status and time to treatment (early vs late), are shown in figure 2 .
Second, we limited the sample to target mismatch patients with reperfusion and constructed a model with time to treatment as the independent variable and good functional outcome as the dependent variable. This model showed no significant association between time to treatment and good functional outcome in unadjusted (p 5 0.17) or adjusted analyses (p 5 0.19) (figure 3).
Third, we assessed predictors of lesion growth in target mismatch patients. Within the early (#6 hours) treated cohort, median lesion growth was 12.8 mL (IQR 1.1-49.7) among nonreperfusers (n 5 12) vs 3.2 mL (IQR 21.7 to 11.9) among reperfusers (n 5 22) (p 5 0.07). In the late (.6 hours) treated cohort, median lesion growth was 37.8 mL (IQR 15.3-116.2) among nonreperfusers (n 5 16) vs 1.3 mL (IQR 21.9 to 12.5) among reperfusers (n 5 24) (p , 0.001). In multivariate analysis, reperfusion was associated with attenuation of lesion growth (p , 0.001), whereas time to treatment and the interaction between reperfusion and time to treatment were not (p 5 0.3 for both). After adjusting for baseline DWI lesion volume, reperfusion remained the only significant predictor of lesion growth (p 5 0.02). When the above analyses were repeated with "time to end of procedure" as the time measure instead of "time to start of procedure," the overall results were unchanged. DISCUSSION This study suggests that the association between endovascular reperfusion and good functional outcome is not time-dependent in patients with Effect of time to treatment on the association between reperfusion and good functional outcome
The adjusted odds ratio (OR) for good functional outcome with reperfusion in patients with the target mismatch (n 5 78) is displayed as a function of time from stroke onset to the start of the endovascular procedure. The 95% confidence interval (CI) is indicated by dashed lines. The association between reperfusion and good functional outcome is not modified by time to treatment in patients with target mismatch (adjusted p value for the interaction between reperfusion and time to treatment 5 0.6). Values are derived from a multivariate logistic regression model adjusted for age and baseline diffusionweighted imaging lesion volume.
Figure 2 Day 90 modified Rankin Scale scores among patients with the target mismatch stratified by treatment time and reperfusion status
The distribution of the 90-day modified Rankin Scale (mRS) scores is shown for target mismatch patients stratified by treatment time (#6 hours vs .6 hours) and reperfusion status. Based on multivariate logistic regression, reperfusion is associated with an increased chance of good functional outcome (odds ratio adjusted for age and baseline diffusion-weighted imaging lesion volume 4.0, 95% confidence interval 1.3-13, p 5 0.02), whereas time to treatment (p 5 0.6) and the interaction between reperfusion and time to treatment are not (p 5 0.6).
evidence of salvageable brain tissue on MRI (i.e., patients with the target mismatch pattern on MRI) who are treated up to 12 hours after symptom onset. Similarly, the association between reperfusion and attenuation of lesion growth is not time-dependent in this patient population. Several analyses were performed to address whether these findings may be due, in part, to a bias toward more favorable characteristics among patients who were treated late. Prior studies have shown that baseline DWI lesion volume and the degree of reperfusion are associated with clinical outcome. 16, [19] [20] [21] In our study, these variables did not differ between early and late treated patients. Other characteristics were also well-matched, except for an expected lower rate of IV tPA treatment in the late treatment group. Among patients with reperfusion, patients treated late had a slightly lower median baseline NIH Stroke Scale score (13.5 vs 14.5) and had an occlusion of the internal carotid artery less frequently (21% vs 36%). While these differences could have biased our secondary analysis (the effect of time to treatment on good functional outcome in the subgroup of patients with reperfusion), this is unlikely because adjusting for these variables did not alter the results of the secondary analysis. Similarly, patient characteristics were well-matched between patients with and without reperfusion, arguing against bias affecting our primary analysis. Consequently, the unadjusted and adjusted primary analyses yielded similar results: both showed that reperfusion is significantly associated with good functional and radiologic outcomes and that these associations are independent of the time to treatment.
The current study differs in 3 important ways from earlier analyses that have assessed the effect of time to endovascular treatment on patient outcomes. The first difference is that the primary analysis of the current study focused on patients with evidence of salvageable tissue on MRI, whereas prior studies included patients regardless of their imaging pattern. In a recent subanalysis of the Interventional Management of Stroke (IMS) III study, time to angiographic reperfusion was an independent predictor of good functional outcome following endovascular therapy (adjusted relative risk for every 30-minute delay 0.88). 6 Our study demonstrates that this association is lost when imaging criteria are applied that limit the population to patients with salvageable tissue ( figure  1) . Together, these studies support the notion that time to treatment is a valid surrogate for tissue at risk but that the MRP-DWI mismatch is a more direct measure of tissue at risk that allows for a more individualized approach to patient selection. A second difference is that prior studies have focused on the probability of good outcome in patients who reperfuse, whereas our primary analysis focused on the effect of reperfusion in patients who reperfused vs those who did not reperfuse. However, in order to compare our results directly with those of previous studies, we also report an analysis that is limited to patients who reperfuse ( figure 3) . In this subanalysis, we again showed no effect of time to treatment on good functional outcome among patients with Effect of time to treatment on the probability of good functional outcome with reperfusion
The probability of good functional outcome in patients with target mismatch who achieved reperfusion (n 5 46) is displayed as a function of time from stroke onset to the start of the endovascular procedure. The 2 curved light blue lines indicate the 95% confidence interval (CI). Short horizontal black lines indicate the mean observed probability of good functional outcome in patients grouped (n 5 7 or 8) according to their consecutive time from symptom onset to start of procedure. Black ovals indicate the mean time from symptom onset to start of procedure for each of the 6 subgroups. Blue circles indicate the observed outcome for each individual patient in the cohort, where 0 corresponds to a modified Rankin Scale (mRS) score .2 and 1 to an mRS score #2 at day 90. "p for trend" is the adjusted p value for the association between time to treatment and the probability of good functional outcome (p 5 0.2). Values are derived from a logistic regression model with time from stroke onset to start of the endovascular procedure as the predictor variable. Probabilities are adjusted for age and baseline diffusion-weighted imaging lesion volume.
salvageable tissue on MRI. A third difference lies in the availability of early follow-up MRI data in our study. These data allowed us to assess the effect of time to treatment on both clinical and radiologic outcomes. Earlier studies have shown that reperfusion is associated with attenuation of lesion growth. 16, 21, 22 Here we confirm those results and also show that the effect of reperfusion on the attenuation of lesion growth is not dependent on time to treatment in patients with salvageable tissue. These results are in line with a recent study that showed attenuation of infarct growth with recanalization in a select cohort of patients who were treated with endovascular therapy more than 8 hours after symptom onset. 23 This study has some limitations. First, the DEFUSE 2 study was not powered for this post hoc analysis. Therefore, a small modifying effect of time to treatment on the association between reperfusion and favorable outcome could have been missed. However, there was not even a trend toward a decline in the benefit from reperfusion with later treatment, making it unlikely that a strong association would have been present in a larger study. Second, we primarily assessed the effect of time to treatment in the subset of patients with a target mismatch because patients without a target mismatch are underrepresented in the DEFUSE 2 cohort, potentially because of selection bias. 12 Other patient groups may also have been underrepresented because they were judged to be poor candidates for endovascular therapy by DEFUSE 2 investigators. This could include patients who were older or who had other unfavorable clinical characteristics. The proportion of patients that was excluded from DEFUSE 2 because they were deemed poor candidates for endovascular therapy and the baseline characteristics of these patients are unknown. A comparison with the Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE) study demonstrates that in DEFUSE 2 the proportion of patients with penumbral tissue is higher (79% in DEFUSE 2 vs 55% in MR RESCUE) and the infarct core volumes of penumbral patients is smaller (median 13 mL in DEFUSE 2 vs 36 mL in MR RESCUE). 16, 20 Third, patients enrolled in DEFUSE 2 were treated between 2.3 and 14.5 hours after symptom onset. The results of this analysis therefore apply only to this time window and should not be extrapolated to treatment at later times. Finally, DEFUSE 2 was a cohort study and not a randomized controlled trial, so the results should be interpreted in that context. Specifically, the results suggest that patients with evidence of salvageable tissue may benefit from reperfusion within a fairly wide time window, but this should not be interpreted as evidence that endovascular therapy is beneficial. That evidence should come from a randomized controlled trial of endovascular therapy vs best medical therapy. The results of this study suggest that a randomized controlled trial that enrolls patients with the target mismatch profile could be designed with a relatively wide time window.
There is convincing evidence from prior studies that earlier stroke treatment is associated with better outcomes. An ongoing effort to expedite the treatment of acute stroke patients, both in clinical practice and in clinical trials, should therefore be strongly encouraged. However, because time is an imprecise surrogate for the presence of salvageable brain tissue, it is also an imperfect criterion for selecting patients who are likely to benefit from reperfusion. Selecting patients with evidence of salvageable tissue on brain imaging is an approach that can personalize the time window for individual patients and potentially widen the time window for the overall population of stroke patients.
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